About RhoGAM1

RhoGAM may help protect your patients from Rh-sensitization. Rh-sensitization of the mother during pregnancy can lead to hemolytic disease of the fetus and newborn (HDFN) in future pregnancies.

#1 RhoGAM is the #1-selling anti-D brand in the US2

RhoGAM is typically administered twice to expectant mothers – once during pregnancy and once after delivery. RhoGAM is an intramuscular injection given by a healthcare professional to the mother.

Antepartum:

  • If the mother’s blood type is Rh-negative, the 1st injection of RhoGAM is delivered between 26-28 weeks of pregnancy

Postpartum:

  • If the baby is found to be Rh-positive at birth, administer within 72 hours of delivery
  • If the baby is determined to be Rh-negative at birth, an additional dose is not needed

Additional doses of RhoGAM are indicated when the patient has been exposed to more than 15 ml of Rh-positive red blood cells.

For complete dosing & administration information, click here for the RhoGAM Full Prescribing Information.


References:
1. RhoGAM Ultra-Filtered PLUS Prescribing Information, 2015. Kedrion Biopharma Inc.
2. The plasma proteins market in the United States, 2015. The Marketing Research Bureau. Orange, CT: 2016.

 

Important Safety Information

RhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (300 μg) and MICRhoGAM® Ultra-Filtered PLUS [Rho(D) Immune Globulin (Human)] (50 μg) are indicated for the prevention of Rh immunization, including during and after pregnancy and other obstetrical conditions or incompatible transfusion of Rh-positive blood.

RhoGAM® and MICRhoGAM® are made from human plasma. Since all plasma-derived products are made from human blood, they may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically the Creutzfeldt-Jakob disease (CJD) agent.

RhoGAM® and MICRhoGAM® are intended for maternal administration. Do not inject the newborn infant. Local adverse reactions may include redness, swelling, and mild pain at the site of injection and a small number of patients have noted a slight elevation in temperature. Patients should be observed for at least 20 minutes after administration.

RhoGAM® and MICRhoGAM® contain a small quantity of IgA and physicians must weigh the benefit against the potential risks of hypersensitivity reactions. Hypersensitivity reactions include hives, generalized urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis. Patients who receive RhoGAM® and MICRhoGAM® for Rh-incompatible transfusion should be monitored by clinical and laboratory means due to the risk of a hemolytic reaction.

You are encouraged to report adverse events of prescription drugs to the FDA.
Visit www.fda.gov/Safety/MedWatch/ or call 1-800-FDA-1088.

Click here for the RhoGAM Full Prescribing Information

This site is intended for residents of the US only.

 

Back to top